~~<i id='0464402732'><strike id='0464402732'><tt id='0464402732'><pre id='0464402732'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

focus

author：fashion 2025-09-03 07:54:46 - browse：1985

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： What health policies could hitch a ride on a spending bill?

hotspot

Wikipedia

hotspot

AdobePHILADELPHIA—Anewstudy,andthebolddoctorwholedit,couldresultinbigquestionsabouthowresearchersstu

WSS

Change Healthcare cyberattack outage could last weeks

Biotech companies concerned about China biosecurity crackdown

Obesity now affects over 1 billion people worldwide, study finds

Clinical trials giant ICON acquires HumanFirst

Covid isolation guidance eased by the CDC

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

knowledge

focus

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA reorg will put new emphasis on investigations, sources say

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Duchenne breakthrough therapy leaves behind pioneering families

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

After affirmative action ruling, medical educators look to 'holistic review'

Medical school prerequisites are outdated

Jerome Adams on the need for new antivirals for Covid

Carbon Health diabetes program, a test of data

hotspot

RSV vaccines may be linked to small increased risk of developing GBS

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Flu vaccine offering decent levels of protection this winter, new data show

How state and local governments are sidelining science

Experimental asthma app from Apple and Anthem shows promise

Obesity now affects over 1 billion people worldwide, study finds

Wikipedia

Wikipedia

Wikipedia

hotspot